Janux Therapeutics (JANX) – Analysts’ Recent Ratings Updates

Janux Therapeutics (NASDAQ: JANX) has recently received a number of price target changes and ratings updates:

• 5/11/2026 – Janux Therapeutics was given a new $22.00 price target by Evercore Inc.
• 5/8/2026 – Janux Therapeutics had its price target lowered by Piper Sandler from $30.00 to $26.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Janux Therapeutics had its price target lowered by Wedbush from $45.00 to $36.00. They now have an “outperform” rating on the stock.
• 5/8/2026 – Janux Therapeutics had its price target lowered by Guggenheim from $68.00 to $58.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Janux Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/28/2026 – Janux Therapeutics had its price target lowered by JonesTrading from $50.00 to $28.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Janux Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/20/2026 – Janux Therapeutics was downgraded by Barclays PLC from “overweight” to “underweight”. They now have a $14.00 price target on the stock, down from $29.00.
• 4/15/2026 – Janux Therapeutics was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $15.00 price target on the stock, down from $57.00.
• 4/5/2026 – Janux Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/28/2026 – Janux Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling at Janux Therapeutics

In other news, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at $457,265.90. This trade represents a 5.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.90% of the stock is owned by insiders.

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.